We investigate the correlation between programmed cell death-ligand 1 (PD-L1) and tumor-associated immune cell (TAIC) density in small-cell neuroendocrine carcinoma of the uterine cervix (SCNEC) and their correlation with clinicopathologic features.
Methods
PD-L1 and mismatch repair protein (MMR) expression in cancer cells and the density of TAIC were evaluated by immunohistochemistry in 89 SCNEC patients. The combined positive score (CPS), tumor proportion score (TPS), and immune cell score (ICS) of PD-L1 were measured, along with their correlation with clinicopathologic features in SCNEC patients using statistical analyses.
Results
CPS of PD-L1 ≥ 1 was seen in 68.5% of patients, positive TPS and ICS of PD-L1 were detected in 59.6% and 33.7% of patients, respectively. PD-L1CPS was higher in tumor-infiltrating immune cells (r = 0.387, p = 0.001) and positively correlated with programmed cell death-1 and forkhead box P3 + regulatory T cell (FOXP3 + Treg) infiltration (r = 0.443, p < 0.001; r = 0.532, p < 0.001). There was no statistical correlation between PD-L1 and MMR status. PD-L1CPS and PD-L1ICS positivity were independent prognostic factors, correlating with a favorable survival (HR (95%CI) = 0.363(0.139–0.950), p = 0.039 and HR (95% CI) = 0.199(0.050–0.802), p = 0.023, respectively). PD-L1ICS positivity was an independent indicator of recurrence in SCNEC patients and associated with better disease-free survival (HR (95% CI) = 0.124(0.036–0425), p = 0.001). TAIC and MMR levels had no statistical impact on survival results.
Conclusions
PD-L1 positivity was seen in over half of SCNEC tumors. It may work synergistically with FOXP3 + Treg and other infiltrating immune cells to support an adaptive immune response. PD-L1 positivity may be a favorable prognostic factor in SCNEC.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
SCNEC
Small-cell neuroendocrine carcinoma of the cervix
TILs
Tumor-infiltrating immune cells
PD-1
Programmed cell death-1
PD-L1
Programmed cell death protein 1 ligand 1
Tregs
Regulatory T cells
FOXP3 +
Tregs regulated by forkhead box P3 +
dMMR
Deficient mismatch repair
TAIC
Tumor-associated immune cell
FIGO
The International Federation of Gynecology and Obstetrics
HPV
Human papillomavirus
NSE
Neuron-specific enolase
TMA
Tissue microarray
PMS2
PMS1 homolog 2
MSH2
MutS homolog 2
MLH1
MutL homolog 1
MSH6
MutS homolog 6
CD20
Membrane spanning 4-domains A1
Ki-67
Marker of proliferation Ki-67
P16
Cyclin dependent kinase inhibitor 2A
CPS
Combined positive score
TPS
Tumor proportion score
ICS
Immune cell score
SPSS
The Statistical Product and Service Solutions
NACT
Neoadjuvant chemotherapy
EP
The cisplatin and etoposide
DFS
Disease-free survival
OS
Overall survival
TAMs
Tumor associated macrophages
SCLC
Small cell lung cancer
FDA
The Food and Drug Administration
Introduction
Small-cell neuroendocrine carcinoma of the cervix (SCNEC) is a rare but lethal cervical malignancy, constituting 0.9–1.5% of invasive cervical cancers and an annual incidence rate of 0.06 per 100,000 women[1, 2]. SCNEC has highly aggressive biological characteristics with high incidence rates of hematogenous (80%) and lymphogenous (45–57%) metastases [3, 4]. Even with advancements in treatment, SCNEC prognosis is poor (including patients diagnosed at early stages of disease) with survival rates for SCNEC patients at all stages ranging between 11–54% [5]. Thus, identifying prognostic factors and novel therapeutic options are strongly warranted for SCNEC patients.
Several studies suggest that tumor-infiltrating immune cells (TILs) with different cell types and densities play a significant role in the prognoses of many tumors, such as lung, breast, and cervical cancer [6‐8]. Programmed cell death-1 (PD-1) regulates effector T cell activity by interacting with one of its ligands, programmed cell death protein 1 ligand 1 (PD-L1), which is expressed on various types of tumor cells including cervical cancer [9], and PD-L1 influences the functional maintenance of regulatory T cells (Tregs), a subset of CD4 + cells [10]. Tregs regulated by forkhead box P3 + (FOXP3 +), a forkhead helix transcription factor, are found in various tumors and are considered as a prognostic factor in human cancers [11‐13]. Deficient mismatch repair (dMMR) and PD-L1 positivity have been shown to predict the benefit of anti-PD-1/PD-L1 immunotherapy in several cancers [14‐16]. Recently, a case study found that PD-L1 expression, mainly focal, occurred in 70% of SCNEC tumors, and loss of MMR occurred in 33% of SCNEC tumors [17].
Anzeige
However, few studies have explored the expression, infiltration, relationship, and prognostic role of immune and anti-immune factors in SCNEC. In this study, we evaluated and explored the correlation between PD-L1 and tumor-associated immune cell (TAIC) levels in SCNEC tumors and investigated their relationship with SCNEC clinicopathological features and prognosis.
Materials and methods
Patients
This study enrolled 89 SCNEC patients who had undergone radical hysterectomy at the Sun Yat-sen University Cancer Center from 2005 to 2019. The last follow-up was in January 2020. The patients were followed up for 1.0–125.7 months. Clinical characteristics were collected including age, the International Federation of Gynecology and Obstetrics (FIGO) stage, tumor size, cervical human papillomavirus (HPV) DNA level, neuron-specific enolase (NSE) serum level, operative reports, histopathology, adjuvant therapy, tumor recurrence, and current status. Staging is based on the FIGO 2018 cervical cancer staging system. This trial was approved by the Sun Yat-sen University Cancer Center Institutional Review Board (YB2019-182–01), where all samples were handled in line with ethical and legal standards.
Tissue microarray (TMA) construction
TMAs were constructed from SCNEC patient samples that were embedded in paraffin, where representative tumor tissue areas were confirmed by two gynecologic pathologists based on hematoxylin–eosin (H&E) staining. Triplicate cores (1 mm2) were randomly punched in the marked tumor areas and placed into recipient paraffin blocks using a tissue microarrayer (Beecher instruments). Then, paraffin blocks were incubated at 37℃ for 15 min (so sample tissues attached to the wax) and cut into 4 mm-thick sections.
Immunohistochemistry (IHC)
All of the IHC markers were executed on the SCNEC tissue microarray slides following the manufacturer’s instructions (as described in our previous publication [18]). We assessed the expression of the following markers in SCNEC tumor samples: PD-L1 (clone SP263, Ventana, 1:150 dilution), PD-1 (clone NAT105, Abcam, 1:100 dilution), FOXP3 (clone 236A/E7, Abcam, 1:300 dilution), PMS1 homolog 2 (PMS2, clone EP51, Agilent, 1:100 dilution), mutS homolog 2 (MSH2, clone FE11, Agilent, 1:150 dilution), mutL homolog 1 (MLH1,clone ES05, Agilent, 1:50 dilution), mutS homolog 6 (MSH6, clone EP49, Agilent, 1:150 dilution), CD3 molecule (CD3, clone 2GV3, Ventana, 1:150 dilution), membrane spanning 4-domains A1(CD20, clone L26, Ventana, 1:100 dilution), CD4 molecule (CD4, clone SP35, Abcam, 1:50 dilution), CD8a molecule (CD8, clone 144B, Dako, 1:100 dilution), CD68 molecule (CD68, clone MRQ-42, Ventana, 1:100 dilution), marker of proliferation Ki-67 (Ki67, clone MIB-1, DAKO, 1:100 dilution), cyclin dependent kinase inhibitor 2A (P16, clone CINecP16,Ventana, 1:100 dilution).
Anzeige
Immunostaining was reviewed and evaluated by two independent pathologists who were blinded to the patients. The percentage of PD-L1 membrane staining in tumor and immune cells and combined positive score (CPS) were evaluated (minimum of 100 cells were evaluated) [19]. The tumor proportion score (TPS) was defined as the percentage of PD-L1-positive tumor cells. When TPS was ≥ 1% (the median value), tumors were considered as “PD-L1TPS positive”. The immune cell score (ICS) was defined by the percentage of PD-L1-positive immune cells. When ICS was ≥ 5% (the median value), tumors were considered as “PD-L1ICS positive”. The CPS was defined as the total number of all PD-L1-positive cells (including tumor cells, lymphocytes, and macrophages) divided by the number of viable tumor cells and multiplied by 100. When CPS was ≥ 1 (the median value), tumors were considered as “PD-L1CPS positive” [20, 21].
PD-1 staining in immune cells was assessed as present (positive) or absent (negative). And the percentage of CD3, CD20, CD4, CD8, CD68 and FOXP3 positive immune cells was obtained by dividing the total number of CD3, CD20, CD4, CD8, CD68 or FOXP3 positive immune cells by the total number of immune cells present in the tissue section. If the infiltration by percent of immune cells was less than the median value, the tumors were classed as having low immune cell infiltration. In addition, P16 was interpreted as positive if diffuse and block-like staining was found in all cores and negative if there was no or patchy staining in the cores. The loss of MMR proteins was defined as complete absence of nuclear staining. Ki67 index was defined by the percentage of positive-stained tumor cells out of a total number of tumor cells (at least 200 cells were evaluated), where “low proliferation” refers to samples that had positive-stained tumor cell percentages that were below the median value.
Statistical analyses
The Statistical Product and Service Solutions (SPSS) 25.0 statistical software package was used to perform all statistical analyses. The association between two variables was assessed by the chi-square test and Fisher’s exact test. Spearman’s rank correlation coefficients were used to calculate the bivariate correlations between the studied variables. Survival curves were plotted using the Kaplan–Meier method, and the log-rank test was used to determine the statistical differences. Multivariate analysis was analyzed using the Cox proportional hazards regression model on all significant characteristics determined using univariate analysis. Values were considered statistically significant when p < 0.05.
Results
Clinical characteristics
The clinicopathological information of the 89 SCNEC patients included in this study is summarized in Table 1. The median age was 44.5 years and the percentages of patients with tumor stages between I–II and III–IV were 59.6% and 40.4%, respectively. The tumor size range was 0.5–9 cm, where almost half of the tumors were of a size that was greater than 4 cm. There were 33 patients (37.1%) receiving neoadjuvant chemotherapy (NACT). Adjuvant chemotherapy was given in 84 (94.4%) patients, which included 55 patients who had also received adjuvant radiotherapy. The cisplatin and etoposide (EP) chemotherapy regimen was the therapy that was used the most in the patients. The total mortality rate was 33.7%, which involved much lower levels in early-stage cancer patients (26.4%) than in advanced-stage cancer patients (44.4%). The rate of tumor recurrence was 46.1%, where patients in early and advanced stages had similar levels.
Table 1
Correlation Between PD-L1 and the Clinicopathological Features of SCNEC
Variable
Total cases
PD-L1TPS*
P-value
(r*)
PD-L1ICS*
P-value
(r)
PD-L1CPS*
P-value
(r*)
Positive
Negative
Positive
Negative
Positive
Negative
Age (years)
< 45
45
26
19
0.830
16
29
0.823
32
13
0.652
≥ 45
44
27
17
(0.037)
14
30
(− 0.04)
29
15
(− 0.056)
FIGO* stage
I-II
53
33
20
0.660
18
35
1.000
35
18
0.644
III-IV
36
20
16
(− 0.067)
12
24
(− 0.007)
26
10
(0.065)
Tumor size(cm)
< 2
11
7
4
0.923
(− 0.043)
4
7
0.932
7
4
0.881
≥ 2, < 4
38
23
15
12
26
(0.008)
27
11
(-0.003)
≥ 4
40
23
17
14
26
27
13
NSE(U/ml)
≤ 15.2
55
31
24
0.804
13
42
0.179
37
18
1.000
> 15.2
23
14
9
(0.042)
9
14
(0.157)
16
7
(0.022)
Stromal invasion
< 1/2
33
22
11
0.373
12
21
0.817
24
9
0.638
≥ 1/2
56
31
25
(− 0.111)
18
38
(− 0.043)
37
19
(− 0.069)
Lymphatic metastasis
No
53
33
20
0.660
18
35
1.000
35
18
0.644
Yes
36
20
16
(− 0.067)
12
24
(− 0.007)
26
10
(0.065)
Parametrium invasion
No
78
48
30
0.341
27
51
0.744
55
23
0.312
Yes
11
5
6
(− 0.108)
3
8
(− 0.051)
6
5
(− 0.113)
LVSI*
No
15
8
7
0.770
5
10
0.760
10
5
0.760
Yes
58
35
23
(0.058)
17
41
(− 0.035)
41
17
(0.035)
PNI*
No
42
26
16
0.788
8
34
0.070
30
12
0.774
Yes
21
12
9
(− 0.046)
9
12
(0.253)
14
7
(− 0.049)
HPV* Infection
Positive
50
32
18
0.145
16
34
1.000
37
1
0.028
Negative
5
1
4
(0.258)
1
4
(0.075)
13
4
(0.336)
P16
Yes
76
48
28
0.128
24
52
0.349
55
21
0.102
No
13
5
8
(0.178)
6
7
(− 0.109)
6
7
(0.199)
Ki67
≥ 70%
53
27
26
1.000
11
35
0.048
33
28
0.648
< 70%
46
19
17
− 0.018
19
24
(− 0.214)
13
15
(0.071)
MMR
dMMR*
17
12
5
0.412
5
12
0.781
12
5
1.000
pMMR*
72
41
31
(0.109)
25
47
(− 0.041)
49
23
(0.021)
NACT*
Yes
32
18
14
0.659
16
16
0.02
23
9
0.643
No
57
35
22
(− 0.05)
14
43
(0.258)
38
19
(0.054)
Postoperative therapy
No
5
4
1
0.644
2
3
1.000
4
1
1.000
Yes
84
49
35
(− 0.102)
28
56
(− 0.032)
57
27
(− 0.06)
Tumor recurrence
No
48
33
15
0.083
(− 0.203)
22
26
0.013
(− 0.278)
11
37
0.071
(− 0.199)
Yes
41
20
21
8
33
17
24
Vital
status
Alive
59
40
19
0.039
(− 0.236)
23
36
0.162
(− 0.156)
16
12
0.003
(− 0.336)
Dead
30
13
17
7
1
14
47
FIGO* International Federation of Gynecology and Obstetrics; LVSI* Lymphovascular invasion; PNI* Perineural Invasion; HPV* Human Papillomavirus; dMMR* deficient mismatch repair; pMMR* proficient mismatch repair; NACT* Neoadjuvant chemotherapy; TPS* the tumor proportion score; ICS* the immune cell score; CPS* Combined Positive Score; r* Spearman’s correlation coefficient;
Immunohistochemical assessment
The immunohistochemical outcomes are summarized in Table 2 and Additional file 1: Fig. S1. PD-L1CPS positivity was seen in 68.5% of SCNEC patients, PD-L1TPS and PD-L1ICS positivity was detected in 59.6% and 33.7% of patients, respectively (Fig. 1). The median PD-L1CPS value was 1 (range = 0–60), while the median PD-L1TPS was 1% (range = 0–15%). The median percentage of PD-L1ICS was 5% (range = 0–60%). There were 19.1% of samples that exhibited dMMR (MLH1/PMS2 loss), 70.6% of which had ≥ 1% PD-L1-positive tumor cells, compared to the proficient mismatch repair (pMMR) group, 56.9% of which showed ≥ 1% PD-L1-positive tumor cells (Spearman’s correlation coefficient(r) = 0.109, p = 0.412). The median percentage of Ki-67 index values was 70% (range = 50–95%, interquartile range = 22.5). 87.6% of the SCNEC showed that ≥ 60% of the tumor cells were Ki-67 positive. More than 85.0% of tumor samples showed positive expression for P16 protein. IHC studies revealed that PD1 protein positivity was identified in the immune cells and was found in 50.6% of samples, 10.0% exhibited PD-1 levels above 10%. FOXP3 positive TILs were observed in 62.9% of specimens. The percentage of specimens who had high level of CD3 + , CD20 + , CD4 + , CD8 + , and CD68 + TILs density were 49.4% (median = 6.0%), 56.2% (median = 0.0%), 51.7% (median 3.0%), 50.6% (median 5.0%), and 70.8% (median 2.0%), respectively.
Table 2
Correlation Between PD-L1 and TILs of SCNEC
Variable
Total cases
PD-L1TPS*
P-value
(r*)
PD-L1ICS*
P-value
(r*)
PD-L1CPS*
P-value
(r*)
Positive
Negative
Positive
Negative
Positive
Negative
CD20
Positive
51
37
14
0.005
(0.307)
25
25
< 0.001
(0.390)
42
8
0.001
(0.377)
Negative
38
16
22
5
34
19
20
CD4
High
46
36
10
0.000
(0.394)
18
28
0.370
(0.119)
42
4
< 0.001
(0.507)
Low
43
17
26
12
31
19
24
CD8
High
45
36
9
< 0.001
(0.421)
26
19
< 0.001
(0.515)
41
4
< 0.001
(0.492)
Low
44
17
27
4
40
20
24
CD68
High
63
42
21
0.056
(0.226)
21
42
1.000
(− 0.12)
49
14
0.006
(0.310)
Low
26
11
15
9
17
12
14
CD3
High
45
37
8
< 0.001
(0.467)
23
22
0.001
(0.372)
42
3
< 0.001
(0.540)
Low
44
16
28
7
37
19
25
TILs
High
59
44
15
< 0.001
20
39
1.000
48
11
0.001
Low
30
9
21
(0.429)
10
20
(0.006)
13
17
(0.387)
PD-L1 TPS
53
53
0
–
24
29
0.006
(0.297)
53
0
< 0.001
(0.822)
Neg
36
0
36
6
30
8
28
PD-L1 ICS
Positive
30
24
6
0.006
30
0
–
26
4
0.009
Negative
59
29
30
(0.297)
0
59
35
24
(0.278)
PD-L1 CPS
Positive
61
53
8
< 0.001
26
35
0.009
61
0
–
Neg
28
0
28
(0.822)
4
24
(0.278)
0
28
PD-1
Positive
45
33
12
0.01
(0.284)
23
22
0.001
(0.372)
40
5
< 0.001
(0.443)
Negative
44
20
24
7
37
21
23
FOXP3
High
56
43
13
< 0.001
(0.457)
25
31
0.005
(0.301)
49
7
< 0.001
(0.532)
Low
33
10
23
5
28
12
21
TPS* the tumor proportion score; ICS* the immune cell score l; CPS* Combined Positive Score; r* Spearman’s correlation coefficient
Fig. 1
The IHC of PD-L1 in SCNEC patients. A, E the IHC of PD-L1TPS negative. B, F The IHC of PD-L1TPS positive. C, G The IHC of PD-L1ICS negative. D, H The IHC of PD-L1.ICS positive. (The scale bar is 200 μm)
×
Correlation of PD-L1 with clinicopathological features
PD-L1TPS, PD-L1ICS, and PD-L1CPS were associated with many clinicopathological parameters of SCNEC (Table 1). PD-L1CPS positivity was positively associated with HPV infection (r = 0.336, p = 0.028). We also showed that PD-L1CPS and PD-L1TPS positivity was associated with a favorable prognosis (r = − 0.336, p = 0.003 and r = − 0.236, p = 0.039, respectively). Moreover, PD-L1ICS positivity was negatively associated with Ki67 proliferation (r = − 0.214, p = 0.048) and tumor recurrence (r = − 0.278, p = 0.013).
PD-L1ICS value increased in the patients who received NACT (r = 0.258, p = 0.02). However, there was no statistical correlation between PD-L1 levels from TPS, ICS, and CPS levels and MMR status (Additional file 1: Fig. S2), PD-L1CPS levels also had no statistical correlation with P16 expression (Additional file 1: Fig. S3) and the proliferation of Ki67 (Additional file 1: Fig. S3).
Correlation of PD-L1 with TAICs
PD-L1 and TAIC levels were found to be significantly positively correlated, especially PL-D1CPS (Table 2; Fig. 2). PD-L1CPS value was positively correlated with PD-1 (r = 0.443, p < 0.001), FOXP3 + (r = 0.532, p < 0.001), TILs (r = 0.387, p = 0.001) and other specific TILs, including CD20 + (r = 0.377, p = 0.001), CD4 + (r = 0.507, p < 0.001), CD8 + (r = 0.492, p < 0.001), CD3 + (r = 0.540, p < 0.001), and CD68 + (r = 0.310, p = 0.006) immune cells. In addition, PD-L1TPS value was higher in TILs (r = 0.429, p < 0.001), such as CD20 + (r = 0.307, p = 0.005), CD4 + (r = 0.394, p < 0.001), CD8 + (r = 0.421, p < 0.001), and CD3 + (r = 0.467, p < 0.001) immune cells, and was positively correlated with PD-1 (r = 0.284, p = 0.01) and FOXP3 + (r = 0.457, p < 0.001) Treg infiltration. Moreover, PD-L1ICS value was also significantly positively correlated with PD-1 (r = 0.372, p = 0.001) and FOXP3 + (r = 0.301, p = 0.005), as well as CD20 + (r = 0.390, p < 0.001), CD3 + (r = 0.372, p = 0.001), and CD8 + (r = 0.515, p < 0.001) immune cells. Taken together, these results suggest that PD-L1 and immune cell markers such as PD-1, FOXP3 + , CD20 + , CD4 + , CD8 + , CD3 + , and CD68 + interact.
Fig. 2
The infiltration by different proportion of TILs in PD-L1CPS negative and PD-L1CPS positive groups. A–E The IHC of the infiltration by a low (left side) or high (right part) proportion of CD3/CD4/CD8/CD20/FOXP3 positive immune cells in each group. F The IHC of PD-L1CPS negative and PD-L1CPS positive. G The infiltration by a higher proportion of CD3 positive immune cells in PD-L1CPS positive groups compared with PD-L1CPS negative groups. H The infiltration by a higher proportion of CD4 positive immune cells in PD-L1CPS positive groups compared with PD-L1CPS negative groups. I The infiltration by a higher proportion of CD8 positive immune cells in PD-L1CPS positive groups compared with PD-L1CPS negative groups. G The infiltration by a higher proportion of CD20 positive immune cells in PD-L1CPS positive groups compared with PD-L1CPS negative groups. K The infiltration by a higher proportion of FOXP3 positive immune cells in PD-L1CPS positive groups compared with PD-L1CPS negative groups (The scale bar is 200 μm, *** means p < 0.001)
×
Anzeige
Prognostic significance of PD-L1
To investigate the prognostic significance of PD-L1, we analyzed overall survival (OS) rates and disease-free survival (DFS) rates among SCNEC patients (Tables 3; 4). Univariate and multivariate analyses indicated that PD-L1CPS and PD-L1ICS positivity were independent prognostic factors that were associated with a favorable survival (HR (95%CI) = 0.363(0.139–0.950), p = 0.039 and HR (95% CI) = 0.199(0.050–0.802), p = 0.023, respectively) and that PD-L1ICS positivity was an independent indicator of recurrence in SCNEC patients that was associated with a better DFS (HR (95% CI) = 0.124(0.036–0.425), p = 0.001). Univariate analysis revealed that PD-L1TPS was associated with a favorable OS and DFS, but there was no statistical significance when assessed with multivariate analyses (Fig. 3). TAIC and MMR status had no statistical impact on survival results.
Table 3
Univariate Cox proportional hazards regression analysis for OS and DFS
Variables
OS
DFS
HR (95% CI)
P value
HR (95% CI)
P value
Age (years)(< 45 vs. ≥ 45)
1.035 (0.506–2.119)
0.924
0.993 (0.534–1.847)
0.983
Tumor size(cm)(< 2 vs. ≥ 2, < 4 vs. ≥ 4)
1.658 (0.919–2.993)
0.093
1.254 (0.770–2.042)
0.364
NSE(U/ml) (≤ 15.2 vs. > 15.2)
2.275 (1.046–4.947)
0.038
1.037 (0.498–2.161)
0.922
HPV* Infection(Positive vs. Negative)
0.377 (0.109–1.298)
0.122
0.364 (0.107–1.238)
0.106
FIGO* stage (I–II vs. III–IV)
2.033 (0.991–4.170)
0.048
1.571 (0.842–2.933)
0.156
Stromal invasion (< 1/2 vs. ≥ 1/2)
1.965 (0.874–4.420)
0.102
2.152 (1.073–4.315)
0.031
Lymphatic metastasis (No vs. Yes)
2.033 (0.991–4.170)
0.053
1.571 (0.842–2.933)
0.156
Parametrium invasion (No vs. Yes)
3.251 (1.384–7.633)
0.004
2.849 (1.253–6.476)
0.012
LVSI* (No vs. Yes vs. Na)
6.489 (0.871–48.312)
0.068
3.750 (1.142–12.311)
0.029
PNI* (No vs. Yes vs. Na)
4.479 (1.834–10.938)
0.001
3.065 (1.520–6.182)
0.002
NACT* (Yes vs. No)
1.716 (0.837–3.521)
0.141
0.998 (0.520–1.916)
0.995
Postoperative therapy (No vs. Yes)
0.749 (0.100–5.620)
0.779
0.292 (0.102–0.831)
0.021
P16(No vs. Yes)
0.994 (0.380–2.602)
0.991
1.081 (0.454–2.578)
0.860
Ki67 (≥ 70% vs. < 70%)
MMR(dMMR* vs. pMMR*)
CD20 (Positive vs. Negative)
0.555 (0.259–1.189)
0.130
0.818 (0.438–1.528)
0.529
0.687 (0.262–1.797)
0.444
0.580 (0.243–1.384)
0.219
0.839 (0.408–1.722)
0.631
0.761 (0.410–1.416)
0.389
CD 4 (High vs. Low)
0.761 (0.365–1.588)
0.466
0.997 (0.535–1.857)
0.992
CD 8 (High vs. Low)
0.728 (0.353–1.504)
0.392
0.692 (0.370–1.297)
0.251
CD68 (High vs. Low)
0.928 (0.434–1.986)
0.849
1.146 (0.572–2.294)
0.701
CD3 (High vs. Low)
0.586 (0.278–1.234)
0.160
0.685 (0.366–1.283)
0.238
TILs(High vs. Low)
0.961 (0.460–2.009)
0.916
1.081 (0.556–2.098)
0.819
PD-1(Positive vs. Negative)
0.933 (0.455–1.911)
0.850
1.055 (0.567–1.964)
0.866
FOXP3(High vs. Low)
0.686 (0.332–1.416)
0.308
0.756 (0.403–1.417)
0.383
PD-L1TPS* (Positive vs. Negative)
0.447 (0.215–0.929)
0.031
0.529 (0.284–0.987)
0.045
PD-L1ICS* (Positive vs. Negative)
0.387 (0.163–0.918)
0.031
0.347 (0.158–0.760)
0.008
PD-L1CPS* (Positive vs. Negative)
0.345 (0.167–0.711)
0.004
0.577 (0.306–1.088)
0.089
FIGO* International Federation of Gynecology and Obstetrics;LVSI* Lymphovascular invasion; PNI* Perineural Invasion; HPV* Human Papillomavirus; dMMR* deficient mismatch repair; pMMR* proficient mismatch repair; NACT* Neoadjuvant chemotherapy; TPS* the tumor proportion score; ICS* the immune cell score; CPS* Combined Positive Score
Table 4
Multivariate Cox proportional hazards regression analysis for OS and DFS
Variables
OS1
OS2
DFS
HR (95% CI)
P value
HR (95% CI)
P value
HR (95% CI)
P value
NSE(U/ml) (≤ 15.2 vs. > 15.2)
1.838 (0.591–5-716)
0.293
2.723 (0.683–10.859)
0.156
FIGO* stage (I-II vs. III- IV)
1.266 (0.418–3.832)
0.677
0.688 (0.188–2.523)
0.573
PD-L1CPS* (Positive vs. Negative)
0.363 (0.139–0.950)
0.039
Parametrium invasion (No vs.Yes)
1.215 (0.339–4.358)
0.765
1.871 (0.516–6.787)
0.341
2.791 (0.847–9.200)
0.092
PNI* (No vs. Yes vs. Na)
3.617 (1.361–9.616)
0.010
5.615 (2.072–15.217)
0.001
2.576 (1.135–5.847)
0.024
PD-L1TPS* (Positive vs. Negative)
0.569 (0.210–1.538)
0.266
0.590 (0.266–1.309)
0.194
PD-L1ICS* (Positive vs. Negative)
0.199 (0.050–0.802)
0.023
0.124 (0.036–0.425)
0.001
Stromal invasion (< 1/2 vs. ≥ 1/2)
2.417 (0.826–7.078)
0.107
LVSI* (No vs. Yes vs. Na)
2.693 (0.638–11.376)
0.178
Postoperative therapy (No vs. Yes)
0.148 (0.040–0.538)
0.004
TPS* the tumor proportion score; ICS* the immune cell score; CPS* Combined Positive Score; PNI* Perineural Invasion; LVSI* Lymphovascular invasion
OS1 Multivariate Cox proportional hazards regression analysis of parameters such as NSE, FIGO stage, PD-L1CPS, Parametrium invasion and PNI, for overall survival
OS2 Multivariate Cox proportional hazards regression analysis of parameters such as NSE, FIGO stage, PD-L1TPS, PD-L1ICS, Parametrium invasion and PNI, for overall survival
Fig. 3
The OS and DFS of PD-L1CPS, PD-L1TPS and PD-L1ICS in SCNEC. A–C The OS of PD-L1CPS, PD-L1TPS and PD-L1ICS in SCNEC; D–F The DFS of PD-L1CPS, PD-L1TPS and PD-L1ICS in SCNEC. P values are based on the log-rank test
×
Considering the clinicopathological characteristics, factors including FIGO stage (HR (95% CI) = 2.033(0.991–4.170), p = 0.048), NSE serum level (HR (95% CI) = 2.275(1.046–4.947), p = 0.038), parametrium invasion (HR (95% CI) = 3.251(1.384–7.633), p = 0.004), and perineural invasion (PNI, HR (95% CI) = 4.479(1.834–10.938), p = 0.001) were significantly associated with the survival of SCNEC patients. Moreover, multivariate analysis revealed that PNI was also an independent prognostic factor in SCNEC patients (HR (95% CI) = 3.617(1.361–9.616), p = 0.010).
Additionally, there was a negative association between DFS and stromal invasion (HR (95% CI) = 2.152(1.073–4.315), p = 0.031), parametrium invasion (HR (95% CI) = 2.849(1.253–6.476), p = 0.012), PNI (HR (95% CI) = 3.065(1.520–6.182), p = 0.002), lymphovascular invasion (LVSI, HR (95% CI) = 3.750(1.142–12.311), p = 0.029), and a positive correlation between DFS and postoperative therapy (HR (95% CI) = 0.292(0.102–0.831), p = 0.021). Among them, multivariate analysis showed that postoperative therapy (HR (95% CI) = 0.148(0.040–0.538), p = 0.004) was an independent recurrence factor in SCNEC patients (Additional file 1: Fig. S4).
Discussion
The tumor microenvironment, including TILs and tumor associated macrophages (TAMs), has a significant effect on therapy response and clinical results [6, 7, 22, 23]. PD-L1 plays a major role in the induction of tumor cell immune evasion by interacting with its receptor PD-1. Recently, immune checkpoint inhibitor therapy has been at the forefront of anti-tumor treatment showing great efficacy [24]. However, the clinical value of the immune microenvironment in SCNEC tumors has not been sufficiently researched.
Anzeige
This study used the largest cohort of SCNEC cases that has been published to date, investigating the association between PD-L1 and clinicopathological features. PD-L1CPS positivity was seen in 68.5% of SCNEC patients, and PD-L1TPS and PD-L1ICS positivity was detected in 59.6% and 33.7% of patients, respectively. Though without statistical significance, PD-L1 expressed higher in tumor cells in SCNEC patients with dMMR than in those with pMMR. The result was in accordance with a 10-case study in SCNEC patients, which found that PD-L1TPS positivity is seen in 70% of SCNEC and is associated with dMMR [17]. Consequently, dMMR may be able to identify those SCNEC patients who may benefit from PD-L1 inhibitors but needs further investigation.
PD-L1 was found to be significantly positively correlated with levels of TAICs, especially PD-L1CPS. PD-L1CPS value was higher in TILs, such as CD3 + , CD4 + , CD8 + , CD20 + , CD68 + immune cells, and was positively correlated with PD-1 and FOXP3 + Treg infiltration with statistical significance. These findings revealed a relationship between the PD-L1/PD-1 pathway and TILs. Much evidence has indicated that the PD-L1/PD-1 pathway is correlated with the maintenance of the immune microenvironment. PD-L1 positivity was correlated with TILs in many tumors, such as osteosarcoma, soft tissue sarcoma, and cervical cancer [17, 25‐27]. Several studies showed that PD-L1 has an important effect on sustaining Tregs function in some autoimmune diseases, such as FOXP3 positive TILs and regulating signaling molecules that play a critical role in transforming naive T cells into Tregs [28, 29]. There are two mechanisms for the regulation of PD-L1 TPS including innate and adaptive immune regulation [30]. One is the tumoral constitutive PD-L1 and the other is an adaptive immune response to local inflammatory signals. In our study, PD-L1 may have an effect on the TIL-mediated anti-tumor inflammatory response in SCNEC.
The combined survival rates of SCNEC range from 11 to 54% for all stages [5]. The OS for early-stage SCNEC patients is 30% to 60%, while the 5-year OS for advanced stages is 0% to 17% [31]. Similarly, in our study, the total mortality rate of SCNEC patients was 33.7%, where patient mortality in early stages was 26.4%, which was lower than that of advanced patients (44.4%). Considering the prognosis of SCNEC patients, PNI was an independent prognostic factor and postoperative therapy was an independent recurrence factor in SCNEC patients. PNI may prove to be another metastatic route in cervical cancer [32]. In small cell lung cancer (SCLC), ASCL1 and NEUROD1 could regulate various genes such as SOX2, MYCL1, that contribute to neuronal function and promote perineural invasion [33, 34]. Since PNI is associated with poor survival of SENEC patients, selecting an appropriate surgical method without nerve-sparing methods is significantly important. And postoperative therapy is necessary for some SCNEC patients to reduce the risk of tumor recurrence.
In addition, we identified that PD-L1CPS and PD-L1ICS positivity were independent favorable prognostic indicators and that PD-L1ICS positivity was an independent favorable recurrence factor in SCNEC patients. This study identified a relationship between improved survival of SCNEC patients and PD-L1, indicating that local immunity plays a critical role in limiting tumor progression. Recently, PD-L1 has been classed as an adverse prognostic factor for many types of malignancies [35‐38], FOXP3 as the same [27]. One study suggested that PD-L1 is a poor prognostic factor and TILs are favorable prognostic factors in cervical squamous cell carcinoma [39]. The role of PD-L1/PD-1 and TILs in tumors is controversial. A study about SCLC indicated that about 39.3% of patients had PD-L1 protein positivity, and PD-L1 and CD8 + TILs density were associated with better prognoses in patients with SCLC [40].In other studies, PD-L1/PD-1 is also associated with favorable prognoses in various tumors, such as triple negative breast cancer, melanoma, and colorectal cancer [15, 41, 42]. It is difficult to rationalize two diametrically opposed results of PD-L1. With our consideration, one of the reasons that caused this opposed prognostic results of PD-L1 might be related with the different type of cancer and specimens, the different definition of “PD-L1 positive”, and the complex mechanism of PD-L1/PD-1 and TILs.
Anzeige
A next-generation sequencing study of 10 SCNEC patients revealed that genetic alterations involved pathways such as PI3K/AKT/mTOR, MAPK, and TP53/BRCA pathways [43]. In addition, a review of 126 published papers demonstrated that PD-L1, which is regulated by many signaling pathways including PI3K/AKT and MAPK (which can be activated by HPV E6/E7 oncogenes), is associated with HPV-caused cervical cancer carcinogenesis [44]. High-risk HPV infection, especially HPV 18 and HPV 16, participates in the development of SCNEC [45]. In our study, PD-L1CPS positivity was positively correlated with HPV infection, indicating PD-L1 and HPV infection may have some interacting functions which need further research. Another comprehensive sequencing analysis found that PD-L1 and CD8 + TILs are much higher in cervical cancer patients with complete response to chemoradiotherapy than those who did not respond to chemoradiotherapy, indicating an inflammatory tumor microenvironment exists in cervical cancer patients that will respond to chemoradiotherapy [46]. TILs may be a basic predictor of tumor treatment response [47]. All of these studies demonstrate complex mechanisms of PD-L1 and TILs, which may be possible predictors of response to chemoradiotherapy and favorable prognostic indicators in SCNEC patients.
Due to the histopathological similarity to SCLC, the treatment of SCNEC is predominantly based on SCLC, including surgery, radiotherapy, and chemotherapy, which has improved SCNEC patient prognoses to some extent [17]. Researches have suggested that SCLC patients with neuroendocrine (NE)-low subtype are correlated with increased TILs compared to NE-high tumors, providing potential biomarkers for SCLC immunotherapies [48, 49]. Pembrolizumab was approved by the Food and Drug Administration (FDA) for therapy of patients with metastatic or recurrent cervical cancer with PD-L1positivity (as determined by an FDA-approved test in cervical cancer) and patients with metastatic SCLC. More pembrolizumab related clinical research should be carried out in SCNEC.
In conclusion, our study demonstrated that PD-L1 and PD-1 positivity in more than half of SCNEC tumors and may work synergistically with FOXP3 + Treg and other TAICs in support of an adaptive immune response to local inflammatory signals. PD-L1 may be a favorable prognostic factor in SCNEC. Conventional therapies that are in combination with immune modulation treatments, such as a combined strategy to block PD-L1/PD-1 with depletion of FOXP3 + Tregs, may show as a promising treatment for SCNEC patients and may change the course of the disease.
Acknowledgements
We would like to thank the native English speaking scientists of Elixigen Company (Huntington Beach, California) for editing our manuscript.
Declarations
Ethics approval and consent to participate
the Institutional Review Board of Sun Yat-sen University Cancer Center (IRB No.: YB2019-182–01).
Consent for publication
The authors declare that they give their consent for publication.
Competing interests
The authors declare that they have no conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.
Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.
Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.
Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
